A Randomized, Double Blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Doses of BTZ043 in Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs BTZ-043 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 19 Nov 2018 Planned End Date changed from 15 Dec 2018 to 15 Feb 2019.
- 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jul 2018 New trial record